GeoVax develops vaccines and immunotherapies against infectious diseases and solid tumor cancers. GOVX reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 15 | Noble Capital Markets | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in GOVX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GOVX is in one of them and how their past GOVX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GOVX in an article yet. Here's the latest on the wider market.
About GeoVax Labs
GeoVax is a biotechnology company based in Smyrna, Georgia, that develops vaccines and immunotherapies for infectious diseases and solid tumor cancers. Its lead near-term effort is a vaccine candidate against mpox and smallpox, intended to address supply shortages of orthopoxvirus vaccines for public health agencies and biodefense programs. The company also develops Gedeptin, a gene therapy for solid tumors including head and neck cancer, and a COVID-19 vaccine candidate for people with weakened immune systems.
- Headquarters
- Smyrna, GA